Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

5articles mentioning institutions

5institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: NCT03301506 ×

NCT03301506

This institution is selected. Its supporting articles are shown below.

NCT033015065

Articles mentioning NCT03301506

5 articles · page 1 of 1

P54 36 months of treatment with seladelpar is associated with stable or improved liver stiffness in patients with primary biliary cholangitis

gutjnl · abstract · 2026-06-23 · 1 matching annotations

87.6%

NCT03301506 NCT04620733 seladelpar primary biliary cholangitis (PBC)PBC ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA SEL UDCA

…erim analysis of the ongoing, open-label Phase 3 ASSURE study ( NCT03301506).Methods Patients enrolled in ASSURE from the placebo-controlle…

P57 Improvements in moderate-to-severe pruritus patients with primary biliary cholangitis treated with seladelpar in up to 30 months of ASSURE

gutjnl · abstract · 2026-06-23 · 1 matching annotations

84.3%

NCT04620733 NCT03301506 Numeric Rating Scale Seladelpar primary biliary cholangitis PBC PBC-40 SEL

…ritus in the pivotal, placebo (PBO)-controlled RESPONSE study ( NCT04620733). We report long-term pruritus outcomes from the RESPONSE study…

P62 Seladelpar linked to sustained reduction in cholestatic markers with consistent safety profile in PBC up to 48 months in ASSURE

gutjnl · abstract · 2026-06-23 · 1 matching annotations

82.5%

NCT04620733 NCT03301506 seladelpar primary biliary cholangitis (PBC)PBC SEL ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA

…lling over from the placebo-controlled, Phase 3 RESPONSE trial (NCT04620733) or with prior participation in legacy SEL trials. Phase 2 and …

P28 Seladelpar treatment of patients with primary biliary cholangitis improves the GLOBE score and predicts improved transplant-free survival

gutjnl · abstract · 2025-10-06 · 1 matching annotations

85.2%

NCT03301506 NCT04620733 Seladelpar primary biliary cholangitis PBC

…ONSE ( NCT04620733) trial and its open-label extension (ASSURE; NCT03301506).Patients with PBC who received UDCA for ≥12 months (M) or were…

P29 Efficacy and safety of seladelpar in patients with primary biliary cholangitis previously treated with fibrates or obeticholic acid

gutjnl · abstract · 2025-10-06 · 1 matching annotations

87.9%

NCT03301506 primary biliary cholangitis seladelpar delpar OCA

…ts completing RESPONSE were eligible to roll over into ASSURE ( NCT03301506), an ongoing, open-label, long-term, Phase 3 safety trial. Here…